Moreover, genetic or pharmacological inhibition of the class IIb HDAC, HDAC6, improved systolic contractile function independent of cardiac enlargement and fibrosis in a rodent model of hypertension [54]. This evidence concerns the gene HDAC9 and hypertensive disorder.